CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
JR-171 (lepunafusp alfa)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04227600
NCT04227600Phase 2Completed
CompareCT.gov

Phase I/II Study of JR-171 ㏌ Patients With Mucopolysaccharidosis Type I

JCR Pharmaceuticals Co., Ltd.·interventional·Posted Jan 13, 2020·Updated Mar 19, 2025

In Brief

A Phase 2 clinical trial evaluating JR-171 (lepunafusp alfa) for Mucopolysaccharidosis I. Completed, enrolled 18 participants across 6 sites in 3 countries.

Detailed Summary

Phase I/II, open-label, multicenter, multinational (Japan, Brazil and US),designed to evaluate the safety, pharmacokinetics and explore the efficacy for the treatment of mucopolysaccharidosis type I (MPS I).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMucopolysaccharidosis I
CountriesBrazil, Japan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 13, 2020
Enrollment StartSep 1, 2020
Primary CompletionAug 2, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.5 years ago

Interventions

JR-171 (lepunafusp alfa)drug

IV infusion